No Solid Evidence to Support GEP Testing in Thin Melanoma
Most studies that have looked at 31-GEP testing in melanoma have been retrospective or prospective, and did not involve a comparator group.
All articles by Agata Boxe
Thyroid Dysfunction During Anti–PD‐1 Immunotherapy Linked to Better Survival Outcomes
There was no increase in survival linked to acquired subclinical thyroid dysfunction or preexisting thyroid dysfunction, however.
NBUVB Phototherapy May Not Increase Skin Cancer Risk in Patients With Vitiligo
Many patients with vitiligo undergo multiple courses of phototherapy, which may raise concerns about their risk of photocarcinogenesis.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
Tivozanib Shows Superior Safety Profile Across TKIs in Metastatic Renal Cell Carcinoma
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies for mRCC.
Open Radical Nephrectomy for RCC May Increase Circulating Tumor Cells
The investigators observed significantly higher postoperative CTC counts in the open radical nephrectomy group compared with the other 3 groups in the study.
New Vaccine Could Delay ADT Use in Stage D0 Prostate Cancer
If the vaccine is shown to work, it may help delay the use of ADT in such patients, Dr Maeng said.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Ibrutinib Shown to Cross the Blood-Brain Barrier in CNS Lymphoma
The authors proved that the drug was able to cross the blood-brain barrier in a concentration that was effective.
-
Loading...
-
Loading...
Next post in Lymphoma
